CompletedNot Applicable

Basal Cell Carcinoma Recurrence After Mohs Surgery

United States115 participantsStarted 2008-05

Plain-language summary

Basal cell carcinoma (BCC) is the most common skin cancer in the US and can cause significant adverse effects. Mohs micrographic surgery, the treatment of choice for higher risk BCC, allows for removal of lesions with preservation of healthy tissue. Although the BCC recurrence rate post Mohs surgery is estimated at 1-2%, recent data is lacking to validate this historical measurement. Our purpose is to determine the current recurrence rate of BCC after Mohs surgery.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects with BCC lesions on the head, neck, genitalia, hands, or feet * Subjects who have undergone Mohs micrographic surgery for BCC on or before December 31, 2006 * Subjects with a medical record at the respective site * Subjects in a stable health condition, as determined by the principle investigator Exclusion Criteria: * Subjects with basal cell nevus syndrome * Subjects with lesions only in areas other than the head, neck, genitalia, * hands and feet * Subjects who have not followed up through the Department of Dermatology * Subjects with recurrent BCC lesions diagnosed on or prior to the recorded date of Mohs surgery

What they're measuring

Recurrence of BCC

Timeframe: either after 1 study visit (historical arm), or 3 years (prospective arm)

Trial details

NCT IDNCT00882791

SponsorNorthwestern University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2009-05

View on ClinicalTrials.gov More Basal Cell Carcinoma trials